Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $56.0 million.

  • TransMedics' Accumulated Expenses rose 3278.02% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 3278.02%. This contributed to the annual value of $45.2 million for FY2024, which is 1813.4% up from last year.
  • According to the latest figures from Q3 2025, TransMedics' Accumulated Expenses is $56.0 million, which was up 3278.02% from $42.5 million recorded in Q2 2025.
  • TransMedics' Accumulated Expenses' 5-year high stood at $56.0 million during Q3 2025, with a 5-year trough of $9.9 million in Q1 2021.
  • Its 5-year average for Accumulated Expenses is $28.0 million, with a median of $22.9 million in 2023.
  • Per our database at Business Quant, TransMedics' Accumulated Expenses grew by 5.04% in 2021 and then soared by 10510.33% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Accumulated Expenses stood at $16.3 million in 2021, then rose by 14.07% to $18.6 million in 2022, then surged by 105.1% to $38.2 million in 2023, then rose by 18.13% to $45.2 million in 2024, then increased by 24.06% to $56.0 million in 2025.
  • Its Accumulated Expenses stands at $56.0 million for Q3 2025, versus $42.5 million for Q2 2025 and $40.1 million for Q1 2025.